Peter Kolchinsky latest buys and sells
53 buys and sells in Peter Kolchinsky's latest 13F filing, largest first. The largest is the new position in PBLS, $791.9M or 6.9% of the reported portfolio.
Key facts
- Moves
- 53
- New positions
- 16
- Complete sales
- 17
- Largest move
- PBLS, $791.9M
- Latest filing
- Aug 14, 2026
From RA Capital Management's filing for (Q2 2026), filed , against the filing for Mar 31, 2026.
| # | Stock | Move | Shares | Size | Of portfolio |
|---|---|---|---|---|---|
| 1 | Parabilis Medicines IncPBLS | ▲ New | +28.93M | $791.9M | 6.88% |
| 2 | Hemab Therapeutics HoldingsCOAG | ▲ New | +7.81M | $286.8M | 2.49% |
| 3 | Dianthus Therapeutics IncDNTH | ▼ Sold out | — | $219.2M | 1.90% |
| 4 | Nuvalent Incno ticker on file | ▼ Reduced 51% | −1.29M | $159M | 1.38% |
| 5 | Abivax SAABVX | ▲ New | +1.13M | $150.9M | 1.31% |
| 6 | Oruka Therapeutics IncORKA | ▲ New | +1.55M | $148M | 1.29% |
| 7 | Praxis Precision MedicinesPRAX | ▼ Sold out | — | $120.4M | 1.05% |
| 8 | Sarepta Therapeutics IncSRPT | ▼ Sold out | — | $84.9M | 0.74% |
| 9 | Edgewise Therapeutics IncEWTX | ▼ Reduced 20% | −2.04M | $82.7M | 0.72% |
| 10 | Spyre Therapeutics IncSYRE | ▼ Sold out | — | $81.8M | 0.71% |
| 11 | Artiva Biotherapeutics IncARTV | ▲ Added 82% | +8.1M | $78.6M | 0.68% |
| 12 | Intellia Therapeutics IncNTLA | ▲ New | +4.53M | $76.6M | 0.67% |
| 13 | Definium Therapeutics IncDFTX | ▲ New | +1.5M | $70.6M | 0.61% |
| 14 | Sana Biotechnology IncSANA | ▲ New | +18.75M | $65.4M | 0.57% |
| 15 | Vor Biopharma IncVOR | ▼ Reduced 56% | −3M | $55.3M | 0.48% |
| 16 | Fulcrum Therapeutics IncFULC | ▼ Sold out | — | $46.4M | 0.40% |
| 17 | Olema Pharmaceuticals IncOLMA | ▼ Sold out | — | $38.8M | 0.34% |
| 18 | Prelude Therapeutics IncPRLD | ▲ New | +6.48M | $34.5M | 0.30% |
| 19 | Design Therapeutics IncDSGN | ▼ Sold out | — | $31.6M | 0.27% |
| 20 | Aclaris Therapeutics IncACRS | ▲ Added 87% | +5.92M | $31.3M | 0.27% |
| 21 | Q32 Bio IncQTTB | ▲ New | +2.33M | $29.7M | 0.26% |
| 22 | Editas Medicine IncEDIT | ▲ New | +8.89M | $28.8M | 0.25% |
| 23 | Solid Biosciences IncSLDB | ▲ Added 29% | +2.7M | $26.9M | 0.23% |
| 24 | Geron CorpGERN | ▼ Reduced 33% | −20.96M | $26.8M | 0.23% |
| 25 | Travere Therapeutics IncTVTX | ▼ Sold out | — | $22.2M | 0.19% |
| 26 | Grail IncGRAL | ▼ Sold out | — | $22.1M | 0.19% |
| 27 | Relmada Therapeutics IncRLMD | ▼ Sold out | — | $20.5M | 0.18% |
| 28 | Altimmune IncALT | ▲ New | +6.5M | $19.8M | 0.17% |
| 29 | Faeth Therapeutics IncFTH | ▲ New | +722.02K | $18.1M | 0.16% |
| 30 | Sutro Biopharma IncSTRO | ▼ Sold out | — | $17.8M | 0.15% |
| 31 | Aura Biosciences IncAURA | ▲ New | +2.5M | $17.8M | 0.15% |
| 32 | Contineum Therapeutics IncCTNM | ▼ Sold out | — | $16.9M | 0.15% |
| 33 | Inspire Med Systems IncINSP | ▼ Sold out | — | $16.8M | 0.15% |
| 34 | Seaport Therapeutics IncSPTX | ▲ New | +700K | $15.2M | 0.13% |
| 35 | Hinge Health IncHNGE | ▼ Sold out | — | $14.1M | 0.12% |
| 36 | GeneDx Holdings CorpWGS | ▼ Sold out | — | $13.5M | 0.12% |
| 37 | Atrium Therapeutics IncRNA | ▼ Sold out | — | $11.6M | 0.10% |
| 38 | Acrivon Therapeutics IncACRV | ▲ Added 47% | +3.89M | $6.9M | 0.06% |
| 39 | Avalo Therapeutics IncAVTX | ▲ Added 51% | +337.05K | $6.2M | 0.05% |
| 40 | Aktis Oncology IncAKTS | ▼ Reduced 13% | −188.63K | $6.1M | 0.05% |
| 41 | Xencor IncXNCR | ▲ Added 7.7% | +377.08K | $6.1M | 0.05% |
| 42 | Jatt II Acquisition CorpJATT | ▲ New | +500K | $5.7M | 0.05% |
| 43 | Maplight Therapeutics IncMPLT | ▼ Sold out | — | $5M | 0.04% |
| 44 | Amanat Acquisition CorpAMAN | ▲ New | +375K | $3.8M | 0.03% |
| 45 | Adicet Bio IncACET | ▼ Reduced 21% | −250.01K | $2.2M | 0.02% |
| 46 | Werewolf Therapeutics IncHOWL | ▼ Reduced 64% | −4.29M | $1.5M | 0.01% |
| 47 | Rezolute IncRZLT | ▲ Added 2.9% | +265.3K | $1.4M | 0.01% |
| 48 | GH Research PLCGHRS | ▼ Reduced 0.5% | −39.92K | $1.1M | 0.01% |
| 49 | Zai Lab LtdZLAB | ▲ Added 0.6% | +36.53K | $694K | 0.01% |
| 50 | Ovid Therapeutics IncOVID | ▼ Reduced 2.0% | −213.21K | $573.5K | 0.00% |
| 51 | Bioage Labs IncBIOA | ▲ Added 1.3% | +20.96K | $513.8K | 0.00% |
| 52 | Palatin Technologies IncPTN | ▼ Reduced 11% | −7.88K | $85K | 0.00% |
| 53 | Damora Therapeutics IncDMRA | ▲ Added 0.02% | +480 | $12.5K | 0.00% |
Questions and answers
What did Peter Kolchinsky buy last quarter?
The largest purchases in the latest 13F filing: PBLS, $791.9M; COAG, $286.8M; ABVX, $150.9M; ORKA, $148M; ARTV, $78.6M; NTLA, $76.6M.
What did Peter Kolchinsky sell last quarter?
The largest sales in the latest 13F filing: DNTH, $219.2M; Nuvalent Inc, $159M; PRAX, $120.4M; SRPT, $84.9M; EWTX, $82.7M; SYRE, $81.8M.
How is the size of a buy or sell worked out?
As the change in shares at the price the filing implies for the quarter's end (reported value divided by shares) — an estimate of the trade, not what was paid. A position sold out is sized at its value in the previous filing.
Learn
Cite this page
Funkfolio, “Peter Kolchinsky: buys and sells, Q2 2026 13F”, data as of 14 August 2026. https://funkfolio.com/gurus/activity?investor=peter-kolchinsky
Underlying data: SEC EDGAR, Form 13F-HR.
Source: SEC EDGAR, Form 13F-HR. A move is a change in share count between an investor's latest filing and the one before; a share split in between is allowed for where one is on record. Size is the shares bought or sold at the price the filing implies for the period end (reported value ÷ shares) — an estimate of the trade, not what was paid — and a position sold out is sized at its value in the previous filing. “Of portfolio” sets that size against the portfolio reported for the period. Only each investor's 150 largest positions and 50 largest exits are read. Filings appear up to 45 days after the quarter ends; none of this is advice.